Replimune

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Replimune is committed to leveraging the power of immunotherapy to make a meaningful difference in the lives of cancer patients.

Replimune's vision is to become an innovative leader in the development and commercialization of oncolytic immunotherapies to treat cancer and enable better patient outcomes.

Replimune has been recognized with several awards, including a 2016 FierceBiotech Fierce 15 award, a 2017 PharmaVoice 100 award, a 2018 Boston Business Journal Chowder Innovation Awards nomination, and a 2018 Massachusetts Life Science Innovation Awards nomination.